Aurora Cannabis Inc
TSX:ACB
Aurora Cannabis Inc
TSX:ACB
Price:
9.2 CAD
-3.77%
Market Closed
Updated:
May 4, 2024
Section:
Relative Value
The Relative Value of one
ACB
stock under the Base Case scenario is
16.3
CAD.
Compared to the current market price of 9.2 CAD,
Aurora Cannabis Inc
is
Undervalued by 44%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ACB
Relative Value
Base Case
16.3
CAD
Undervaluation 44%
Valuation Multiples
Multiples Across Competitors
ACB Competitors Multiples
Aurora Cannabis Inc Competitors
Aurora Cannabis Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CA |
|
Aurora Cannabis Inc
TSX:ACB
|
144.7m CAD | 0.5 | -1.1 | -0.5 | -0.4 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | -5 347 888.9 | -5 459 134.4 | -5 046 864.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
698.5B USD | 19.4 | 113.8 | 55.8 | 63.5 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | -15 783.5 | 3 846.3 | 17 702.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
3.8T DKK | 16.3 | 45.3 | 33.1 | 36.1 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
359.3B USD | 4.2 | 9.3 | 11.5 | 15 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
322.8B USD | 5.3 | 140 | 33.3 | 52.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
186.8B GBP | 5.1 | 39.4 | 140.7 | 225.6 | |
| CH |
|
Novartis AG
SIX:NOVN
|
179.8B CHF | 4.3 | 13.4 | 9.8 | 16.2 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
173.2B CHF | 3 | 15.1 | 8.6 | 10.2 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
157B USD | 2.9 | -508.1 | 12.6 | 20.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
